Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07013279
PHASE3
Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines
Sponsor: Daewoong Pharmaceutical Co. LTD.
View on ClinicalTrials.gov
Summary
To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines
Official title: A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines
Key Details
Gender
All
Age Range
19 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
324
Start Date
2025-07-15
Completion Date
2026-03-31
Last Updated
2025-06-10
Healthy Volunteers
Yes
Conditions
Interventions
BIOLOGICAL
DWP712 inj.
Clostridium botulinum Toxin
BIOLOGICAL
Botox® 100 Units
Clostridium botulinum Toxin
Locations (1)
Chung-Ang University Hosptial
Seoul, South Korea